# Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

> **NCT00675441** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 5 (actual)

## Conditions studied

- Graft-versus-Host Disease

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT00675441
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Terminated due to slow accrual.
- **Last updated:** 2013-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00675441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00675441, "Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00675441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*